{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:03:37Z","timestamp":1793048617004,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.amjcard.2020.02.016","type":"journal-article","created":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T22:01:47Z","timestamp":1583704907000},"page":"1920-1926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"125","author":[{"given":"Ohad","family":"Oren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent R.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-3168","authenticated-orcid":false,"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.02.016_bib0001","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0002","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0003","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0004","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0005","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.amjcard.2020.02.016_bib0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.22514\/SV131.052017.31","article-title":"Derivation and validation of an automated electronic algorithm to identify patients at risk for obstructive sleep apnea","volume":"13","author":"Olatyoe","year":"2017","journal-title":"Signa Vitae"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0007","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41574-019-0161-2","article-title":"The \u2018obesity paradox\u2019 in action with cancer immunotherapy","volume":"15","author":"Lysaght","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/571846","article-title":"Immune response to lipoproteins in atherosclerosis","volume":"2012","author":"Samson","year":"2012","journal-title":"Cholesterol"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2013.11.021","article-title":"Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo","volume":"40","author":"Lim","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.amjcard.2020.02.016_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pnsc.2008.10.001","article-title":"\u03b22 Adrenergic receptor on T lymphocytes and its clinical implications","volume":"19","author":"Fan","year":"2009","journal-title":"Prog Nat Sci"},{"key":"10.1016\/j.amjcard.2020.02.016_bib0012","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients","volume":"11","author":"Na","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"16","key":"10.1016\/j.amjcard.2020.02.016_bib0013","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920301867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920301867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:33:38Z","timestamp":1757572418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920301867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0002914920301867"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.02.016","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}